Review Explores Cutaneous Manifestations of Myelodysplastic Syndrome
By Elana Gotkine HealthDay Reporter
FRIDAY, April 19, 2024 -- Cutaneous manifestations of myelodysplastic syndrome (MDS) are described in a perspective piece published in the April issue of Skin Health and Disease.
Xiang Li Tan, M.B.B.S., from St. George's University Hospitals NHS Foundation Trust in London, and colleagues conducted a systematic review to examine the prevalence, types, and prognostic and therapeutic significance of nonspecific cutaneous manifestations of MDS. Data were included from 88 articles: 67 case reports and 21 case series, with a total of 134 patients.
The researchers identified six common cutaneous manifestations: neutrophilic dermatoses, vasculitis, granulomatous, connective tissue disease (CTD), panniculitis, immunobullous, and other. Cutaneous features occurred at the time of MDS diagnosis, preceded diagnosis, or occurred after diagnosis (25.3, 34.7, and 40.0 percent, respectively). Poor prognosis was seen, with 34.1 percent progressing to acute myeloid leukemia (AML) and 40.2 percent proving fatal. Of those with MDS who progressed to AML, 50 percent had neutrophilic dermatoses. In 39.2 percent of neutrophilic dermatoses, 50 percent of vasculitis, 62.5 percent of granulomatous, and 14.3 percent of CTD, MDS was fatal (median time from onset of cutaneous manifestation: 12.0, 7.5, 15.5, and 7.0 months, respectively).
"Recognition of patterns of cutaneous features in MDS will improve early diagnosis and risk stratification according to subtype and associated prognosis," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Researchers Compare Race-Based, Race-Neutral Lung Function Equations
TUESDAY, May 21, 2024 -- The use of race-based and race-neutral equations for lung-function testing generate similarly accurate predictions of respiratory outcomes, but differ in...
Survival Benefit for Cancer Trial Participants Does Not Persist in Adjusted Analyses
TUESDAY, May 21, 2024 -- In studies using designs addressing sources of bias and confounding, there is no evidence of a survival benefit for cancer trial participants, according...
Genital Talc Use Positively Linked to Ovarian Cancer
TUESDAY, May 21, 2024 -- There is a positive association between use of intimate care products, including genital talc, and ovarian cancer, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.